The Center for Microbiome Informatics and Therapeutics is pleased to announce a new funding opportunity for research grants.
A detailed Description of the announcement can be found here.
An Overview of the Funding Opportunity:
The Center for Microbiome Informatics and Therapeutics was founded to accelerate the development of therapeutics to treat microbiome-associated disease, with a core focus on Inflammatory Bowel Disease (IBD). To support this mission, the Center has established an interdisciplinary translational research program integrating clinical and basic approaches to research. Over the past 3 years the Center has awarded over $4 million to support the development of tools to diagnose, prevent and treat ulcerative colitis and Crohn’s disease. In 2017, we continue to support the most groundbreaking proposals in the field of IBD research, and will also integrate translational research into one or more new microbiome-associated disease.
Announcement Posted: October 17, 2017
Letter of Intent Due Date: November 20, 2017
Invitation to submit Full Proposal Distributed: December 18, 2017
Full Proposals Due: January 29, 2018
Only Invited Full Applications will be Considered for Funding
· Innovation Grants of up to $125,000 each for 1 year in direct costs (plus overhead capped at 25%) to support projects that accelerate translation of basic research to clinical applications
· Pilot Grants of up to $50,000 each for 1 year in direct costs (plus overhead capped at 25%) to support feasibility studies
We are especially interested in proposals that address the following needs:
· Novel, low-cost toolkits for non-invasive, systems-level measurements
· Screening for candidate therapeutic microbes, and/or small molecules
· Determining rules for assembly and/or maintenance of microbial communities in Inflammatory Bowel Disease or other microbiome-associated disease
· Determining the influence of the fungal and viral microbiome in inflammatory Bowel Disease (or other disease areas)
· Function and significance of the altered microbiome in these disease areas:
o Tolerance and Autoimmunity
o Demonstrating the role of the microbiome in determining the Gut-Brain Axis in health and disease